MedTrace Logo

Trial of Oral Valproic Acid for Retinitis Pigmentosa

NCT01233609 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2017-12-02

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to evaluate the efficacy of Valproic Acid (VPA) to both slow the progression of visual function loss and/or to restore visual function in patients with Autosomal Dominant Retinitis Pigmentosa (RP) and to collect safety and tolerability information.

Conditions

Interventions

DRUG

Valproic Acid

One to four 250mg softgels by mouth daily (dose determined by body weight)

DRUG

Placebo

Dosage per subject weight- same schedule as the active comparator

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Foundation Fighting Blindness

    lead OTHER

Principal Investigators

  • Patricia Zilliox, PhD · Foundation Fighting Blindness

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01233609 on ClinicalTrials.gov